Clinuvel Pharmaceuticals Ltd.
Clinuvel Pharmaceuticals Ltd.
Your view on CUVL
Overview
What the company does, where it operates, and who runs it.
About Clinuvel Pharmaceuticals Ltd.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Philippe Jacques Wolgen
- Headquarters
- 535 Bourke Street, Melbourne, VIC, AU
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Philippe Jacques Wolgen
- Headquarters
- 535 Bourke Street, Melbourne, VIC, AU
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders.
In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Clinuvel Pharmaceuticals Ltd., and the rating behind it. CUVL last traded at $5.74; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Clinuvel Pharmaceuticals Ltd.. Starting points for Clinuvel Pharmaceuticals Ltd.: beta 0.57 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. paid $0.03 per share over the last year — a 0.5% yield at the current $5.74 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Clinuvel Pharmaceuticals Ltd.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Clinuvel Pharmaceuticals Ltd. valued side by side against its closest peers. Clinuvel Pharmaceuticals Ltd. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Clinuvel Pharmaceuticals Ltd., and how their positions are changing. At a $289.5M market value, institutional positions materially move Clinuvel Pharmaceuticals Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Clinuvel Pharmaceuticals Ltd. executives and directors. Shares of Clinuvel Pharmaceuticals Ltd. have traded between $5.98 and $9.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. is a $289.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Clinuvel Pharmaceuticals Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Clinuvel Pharmaceuticals Ltd.. Coverage tracks Clinuvel Pharmaceuticals Ltd. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.